Epitalon: The Pineal Gland Peptide Under FDA Review for Insomnia
Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD.
Regulatory Update (April 2026): Epitalon is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026. The committee will evaluate Epitalon for insomnia and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
Epitalon is a short synthetic peptide with a long research history. Russian gerontologist Vladimir Khavinson developed it in the 1980s as a synthetic version of a compound originally isolated from pineal gland extracts. Most English-language readers know Epitalon through the anti-aging and longevity research community, but the FDA is reviewing it for a narrower indication: insomnia. The July 24, 2026 Pharmacy Compounding Advisory Committee meeting will examine whether Epitalon belongs on the Section 503A Bulk Drug Substances List for that use.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | Synthetic tetrapeptide (4 amino acids) modeled after natural pineal extract |
| Sequence | Alanine-Glutamate-Aspartate-Glycine (Ala-Glu-Asp-Gly) |
| Developed by | Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology |
| FDA-reviewed use | Insomnia |
| Other research areas | Melatonin regulation, telomere biology, age-related disease |
| Administration | Subcutaneous injection (most common) |
| FDA status | Not approved; under PCAC review July 24, 2026 for 503A Bulks List inclusion |
What Is Epitalon?
Epitalon is a four-amino-acid peptide with the sequence Ala-Glu-Asp-Gly. Russian researchers created it as a synthetic version of Epithalamin, a natural polypeptide extract derived from bovine pineal glands. The pineal gland regulates circadian rhythm, melatonin production, and sleep-wake cycles. Extracts from the gland had been used experimentally in Russian research since the 1960s. Epitalon was designed to reproduce the active component of those extracts in a stable, pharmaceutically tractable form.
How Epitalon Works
Epitalon appears to act primarily through the pineal gland. Research suggests it stimulates production of melatonin, the hormone that regulates circadian rhythm and promotes sleep onset. It may also support the gland’s broader endocrine function. A separate line of research has examined whether Epitalon influences telomerase activity and telomere length in cells. Studies published in journals including Biogerontology have reported effects on cellular aging markers. The mechanisms behind these observations are still being characterized.
Research on Insomnia and Sleep
Insomnia is the specific indication the FDA is reviewing. The rationale involves Epitalon’s effect on melatonin production. In older adults, pineal function declines and natural melatonin output drops. That decline correlates with the fragmented, shallow sleep many older adults experience. Research has suggested that Epitalon treatment can restore a more normal melatonin rhythm and improve subjective sleep quality in this population. The evidence base is less robust than for sleep medications with larger clinical programs, but the mechanism is biologically plausible and the safety profile has been favorable.
Epitalon and Aging Research
Most of the public interest in Epitalon comes from aging research, not sleep. Russian long-term studies tracked elderly patients receiving Epitalon and reported better outcomes on various health markers, including mortality rates. Cell culture studies have shown effects on telomerase activity. Animal studies have reported extended lifespan in some models. These results have generated substantial enthusiasm in the longevity community. They have also drawn methodological scrutiny because many of the original studies come from a single research group and English-language replication is limited. The FDA review is focused on insomnia specifically, not aging claims.
Administration and Dosing
Epitalon is typically administered by subcutaneous injection. Oral formulations exist but bioavailability is limited because the peptide is broken down in the digestive tract. Treatment protocols usually involve short courses rather than continuous daily dosing. A common approach is a loading cycle of 10 to 20 days, repeated once or twice per year. Any protocol should be supervised by a licensed clinician who can monitor response and adjust as needed.
Safety Profile
Epitalon has a strong safety record in the Russian clinical research that exists. Side effects are typically mild: occasional injection site reactions, mild fatigue, or transient headaches. The peptide is short, biodegradable, and does not accumulate. As with the other peptides under FDA review, long-term safety in diverse patient populations has not been fully established outside the original research base. Patients with active cancer, hormonal disorders, or who are pregnant should discuss Epitalon carefully with a physician before starting therapy.
Regulatory Status and the July 2026 Review
Epitalon is not approved by the FDA for any indication. The PCAC review on July 24, 2026 will evaluate whether it should be added to the Section 503A Bulks List for insomnia. A significant challenge for the committee will be that much of the supporting clinical research exists in Russian-language publications and originates from a small number of research groups. How the committee weighs that evidence will affect not only Epitalon but may set a precedent for how similar peptides are handled in future reviews. Public comments to the docket (FDA-2025-N-6895) are accepted through July 9, 2026 for committee consideration.
Cost and Finding a Clinic
Epitalon is not covered by insurance. Cash-pay costs at compounding pharmacies typically run $150 to $400 per treatment cycle. Because protocols are cyclical rather than continuous, the annual cost is often lower than many daily-dosed peptide therapies. Work with a licensed physician who can evaluate the underlying cause of your insomnia before starting peptide therapy. Our peptide therapy directory lists verified clinics. For broader context, see our guide to peptide therapy.
